Universal Music Group

Business

Eli Lilly Bets Big on Pennsylvania Plant, Fueling Weight-Loss Drug Ambitions and Valuation Debate

Eli Lilly's $3.5 billion investment in a new Pennsylvania facility for injectable weight-loss drugs, including retatrutide, spotlights its aggressive expansion in the obesity market. This strategic move, coupled with strong analyst sentiment and upcoming earnings, intensifies focus on the company's growth trajectory and premium valuation.

Feb 3, 2026

Business

Coastal Financial's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

Shares of Coastal Financial (CCB) have tumbled over 13% in the past month, sparking debate among investors. While a proprietary valuation model suggests the stock is deeply undervalued, its premium P/E ratio tells a conflicting story. We examine the numbers and the broader context for regional banks.

Feb 3, 2026

World

Sources: No Special ICE Operations Planned for Super Bowl Amid Heightened Immigration Tensions

U.S. immigration authorities will not conduct enforcement actions at this Sunday's Super Bowl, sources tell Reuters, as the event becomes a flashpoint in the nation's heated immigration debate.

Feb 3, 2026

Business

Kemper (KMPR) Q4 Earnings Preview: Can the Insurer Overcome Recent Headwinds?

Kemper Corporation is set to report its fourth-quarter earnings Wednesday afternoon, with investors watching closely for signs of stability after a period of mixed performance and sector-wide pressure.

Feb 3, 2026

Business

Matrix Service Q4 Earnings Preview: Can the Industrial Contractor Sustain Momentum?

Matrix Service Company (MTRX) is set to release its fourth-quarter financial results after the market closes Wednesday. Investors will be watching to see if the industrial construction firm can meet elevated revenue forecasts and translate top-line growth into stronger profitability.

Feb 3, 2026

Business

OpenText Shares Slide 14.6% as IBM Veteran Ayman Antoun Named Incoming CEO

OpenText's appointment of former IBM Americas President Ayman Antoun as its new CEO, effective April 2026, has been met with a sharp sell-off. While the move brings deep cloud and AI expertise, investors appear wary of the leadership transition and strategic pivot amid ongoing portfolio restructuring and debt concerns.

Feb 3, 2026

Business

Corpay Q4 Earnings Preview: Can the Payments Giant Sustain Its Momentum?

All eyes are on Corpay (NYSE: CPAY) as the business payments firm prepares to release its quarterly results after Wednesday's closing bell. Analysts project robust revenue growth, but a history of misses adds intrigue to the report.

Feb 3, 2026

Business

Waymo Secures $16 Billion War Chest, Accelerating Global Robotaxi Rollout

Alphabet's self-driving unit Waymo has raised $16 billion in a landmark funding round, valuing the company at $126 billion. The capital injection, backed by major investors including Alphabet and Dragoneer, is set to fuel an aggressive international expansion of its autonomous ride-hailing service.

Feb 3, 2026

Business

Evercore Earnings Preview: Can the Investment Bank Extend Its Outperformance Streak?

As Evercore prepares to report fourth-quarter results, analysts anticipate steady revenue growth. The firm's consistent history of beating estimates and the performance of its peers set the stage for a closely watched announcement.

Feb 3, 2026

Business

McKesson Q4 Earnings Preview: Can the Healthcare Distributor Beat Revenue Expectations?

All eyes are on healthcare giant McKesson as it prepares to report fourth-quarter results. With a history of revenue misses and a slowing growth rate, analysts and investors are keen to see if the company can deliver a positive surprise.

Feb 3, 2026

Business

Globe Life Q4 Earnings Preview: Can the Insurer Beat Expectations Amid Sector Volatility?

Globe Life (NYSE: GL) is set to report its fourth-quarter earnings after the market closes on Wednesday. With the insurance sector facing headwinds, investors are watching to see if the company can deliver growth that outpaces its recent history of revenue misses.

Feb 3, 2026

Business

CDW Earnings Preview: Can the IT Solutions Giant Meet Expectations Amid Sector Headwinds?

CDW Corporation is set to report its fourth-quarter earnings before the market opens on Wednesday. Analysts project modest revenue growth, but the company's recent performance and broader sector trends suggest a cautious outlook.

Feb 3, 2026

Business

Nektar's Rezpeg Shows Promise Beyond Eczema, Fueling Bullish Outlook for Immunology Platform

New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.

Feb 3, 2026

Business

Houlihan Lokey Poised for 2026 Gains as Market Volatility Fuels Demand for M&A and Restructuring Expertise

Amid forecasts of rising economic stress and market volatility in 2026, investment bank Houlihan Lokey (NYSE: HLI) is attracting bullish attention for its dual strength in M&A advisory and corporate restructuring. Analysts point to its defensive positioning and potential to capture outsized gains in a shifting financial landscape.

Feb 3, 2026

World

Philippine Congress Weighs Historic Impeachment Move Against President Marcos Jr.

Lawmakers in the Philippines are deliberating whether to advance impeachment complaints against President Ferdinand Marcos Jr., setting the stage for a political showdown that could test the stability of his administration.

Feb 3, 2026

US

DHS Chief Noem to Face Congress Amid Scrutiny Over Minnesota Immigration Operations

Homeland Security Secretary Kristi Noem will testify before House and Senate committees in March, as lawmakers probe the administration's immigration enforcement tactics following the fatal shootings of two U.S. citizens in Minnesota.

Feb 3, 2026

Business

Abivax's Lead Drug Shows Promise in Refractory Ulcerative Colitis, Fueling Investor Optimism

French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.

Feb 3, 2026

Business

Lockheed Martin's Strategic Moat: Why Defense Giant's Integration Expertise Fuels Bullish Outlook

Amid rising global tensions and sustained U.S. defense spending, Lockheed Martin's unique role in stitching together America's missile and space defense architecture presents a compelling investment case, analysts argue.

Feb 3, 2026

World

Behind the Handshake: Vietnam's Military Sees U.S. as 'Belligerent' Threat Despite Strategic Partnership

A year after Hanoi and Washington elevated ties to a Comprehensive Strategic Partnership, an internal Vietnamese military document reveals deep-seated fears of U.S. aggression and 'color revolutions,' highlighting the complex duality at the heart of Vietnam's foreign policy.

Feb 3, 2026

Business

General Dynamics: Defense and Aerospace Giant Powers Ahead, But Valuation Questions Loom

Buoyed by a record defense backlog and a surging Gulfstream business, General Dynamics (GD) is generating robust cash flow. However, analysts debate whether its premium valuation already reflects this strong operational momentum, leaving new investors watching for a better entry point.

Feb 3, 2026